Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline

Fineline Cube Dec 30, 2025
Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Fineline Cube Dec 30, 2025
Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix

Fineline Cube Dec 30, 2025
Company Drug

J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial

Fineline Cube Dec 30, 2025
Company Deals

Liaoning Chengda Biotech to See Actual Controller Change of Controlling Shareholder

Fineline Cube Feb 13, 2025

China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) announced a proposed change in the actual...

Company Drug

Bayer’s Acoramidis (Beyonttra) Gets EMA Marketing Approval for ATTR-CM Treatment in EU

Fineline Cube Feb 13, 2025

Germany-headquartered Bayer (ETR: BAYN) has received marketing approval from the European Medicines Agency (EMA) for...

Company Drug

Livzon Pharmaceutical’s JP-1366 Approved for Peptic Ulcer Study by NMPA

Fineline Cube Feb 13, 2025

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has obtained approval from the National Medical Products...

Company Deals

Pfizer Partners with Alloy Therapeutics to Develop New Antibody Platform

Fineline Cube Feb 13, 2025

US pharmaceutical giant Pfizer (NYSE: PFE) has entered into a multi-year partnership with compatriot firm...

Company Medical Device

Lifetech Scientific’s Aortic Stent Graft System Wins NMPA Approval

Fineline Cube Feb 13, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) announced that it has received market approval from the...

Company Deals

Eli Lilly Expands Collaboration with AdvanCell on Targeted Alpha Therapies for Cancer

Fineline Cube Feb 12, 2025

Eli Lilly & Co. (NYSE: LLY) has expanded its collaboration with Australia-based AdvanCell, a clinical-stage...

Company Deals Drug

Eli Lilly Licenses OliX Pharma’s OLX75016 for MASH and Cardiometabolic Diseases

Fineline Cube Feb 12, 2025

Eli Lilly & Co. (NYSE: LLY) has signed a licensing agreement with OliX Pharmaceuticals, Inc....

Company

Gilead Sciences’ Q4 2024 Financials Show 6% Revenue Growth, Driven by HIV and Oncology

Fineline Cube Feb 12, 2025

Gilead Sciences Inc. (NASDAQ: GILD) reported a 6% year-on-year (YOY) increase in global revenues for...

Company Drug

Lion TCR’s Liocyx-M00 Therapy Receives FDA Clearance for HBV-Related HCC Study

Fineline Cube Feb 12, 2025

Singapore-based clinical-stage biotechnology company Lion TCR, backed by Chinese investors, has received clearance from the...

Company Drug

Hainan Poly Pharm’s Generic ProHance Wins FDA Approval in US

Fineline Cube Feb 12, 2025

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) announced that the US Food and Drug...

Company Deals

Kexing Biopharm and Bio-Thera Solutions Form Alliance for Global Expansion

Fineline Cube Feb 12, 2025

China-based Kexing Biopharm (SHA: 688136) and Bio-Thera Solutions Ltd (SHA: 688177) have formed a strategic...

Company Medical Device

MicroPort MedBot’s Toumai Surgical Robot Wins NMPA Approval for Single-Hole Laparoscopy

Fineline Cube Feb 12, 2025

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced that the National Medical Products Administration...

Company Deals

Novartis to Acquire Anthos Therapeutics for $3.1B, Boosting Factor XI Inhibitor Portfolio

Fineline Cube Feb 11, 2025

Swiss pharma giant Novartis (NYSE: NVS) announced plans to acquire Anthos Therapeutics, Inc., a cardiometabolic-focused...

Company Drug

J&J’s Rybrevant and Talvey Win Separate NMPA Approvals in China

Fineline Cube Feb 11, 2025

US pharma giant Johnson & Johnson (J&J, NYSE: JNJ) announced receiving marketing approvals from China’s...

Company Drug

Degron Therapeutics’ DEG6498 Receives FDA Clearance for Clinical Trials

Fineline Cube Feb 11, 2025

China-based Degron Therapeutics, a developer of molecular glue-based drugs, announced that the U.S. Food and...

Company Deals

Roche Transfers InterMune and Esbriet to Legacy Pharma in IP Deal

Fineline Cube Feb 11, 2025

Swiss pharma giant Roche (SWX: ROG) has transferred US-based InterMune, Inc., acquired for USD 8...

Company Drug

Bio-Thera Solutions’ BAT1006 Wins NMPA Approval for HER2+ Breast Cancer Trial

Fineline Cube Feb 11, 2025

China’s Bio-Thera Solutions Ltd (SHA: 688177) has received clinical trial approval from the National Medical...

Company Drug

China Resources Double-Crane Pharmaceutical Co., Ltd Receives NMPA Approval for Generic Purinethol

Fineline Cube Feb 11, 2025

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced that it has received marketing approval...

Company Drug

Henlius Biotech’s HLX99 Receives FDA Approval for ALS Clinical Study

Fineline Cube Feb 11, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

Henlius Biotech Doses First Patient in HLX43 Phase II Study for Esophageal Cancer

Fineline Cube Feb 11, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in a Phase II...

Posts pagination

1 … 151 152 153 … 602

Recent updates

  • Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix
  • Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline
  • J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial
  • HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma
  • Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix

Company Deals

Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline

Company Drug

J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial

Company Drug

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.